Stockscreener 앱 받기
1.18
7.09%
-0.09
시간 외 거래:
1.30
0.12
+10.17%
전일 마감가:
$1.27
열려 있는:
$1.29
하루 거래량:
266.57K
Relative Volume:
1.36
시가총액:
$61.01M
수익:
-
순이익/손실:
$-13.08M
주가수익비율:
-2.6721
EPS:
-0.4416
순현금흐름:
-
1주 성능:
-33.71%
1개월 성능:
-43.81%
6개월 성능:
-71.01%
1년 성능:
-70.86%
1일 변동 폭
$1.18
$1.29
1주일 범위
$1.18
$1.79
52주 변동 폭
$1.18
$8.40
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
명칭
Telomir Pharmaceuticals Inc
전화
786-396-6723
주소
100 SE 2ND ST, MIAMI
TELO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.18 | 61.01M | 0 | -13.08M | 0 | -0.4416 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-21 | 개시 | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc 주식(TELO)의 최신 뉴스
TELO Rises on Promising Telomir-1 Preclinical Results - MSN
Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeriaan Ultra-Rare Genetic Disorder that Causes Rapid Aging - Knoxville News Sentinel
# Telomir-1 shows anti-aging effects in progeria cell study By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals reports positive results for progeria treatment By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals reports positive results for progeria treatment - Investing.com
# Telomir-1 shows anti-aging effects in progeria cell study - Investing.com Australia
Telomir Pharmaceuticals IncTelomir-1 Significantly Increased Cell ViabilitySEC Filing - MarketScreener
Revolutionary Progeria Treatment Shows First-Ever Cellular Aging Prevention in Children's Cells - Stock Titan
EXCLUSIVE: Telomir Pharmaceuticals Says Preclinical Drug Candidate Prevents Premature Aging In Patient-Derived Cells From Children With Progeria - Benzinga
10 Best Growth Stocks Under $100 to Buy Now - Insider Monkey
Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model - The Oklahoman
Telomir-1 shows promise in reversing Wilson’s disease symptoms By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals reports promising drug trial results By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals reports promising drug trial results - Investing.com
Telomir Pharmaceuticals Says Positive Preclinical Results For Telomir-1 In Wilson'S Disease Animal Model - MarketScreener
Telomir-1 shows promise in reversing Wilson’s disease symptoms - Investing.com Australia
Breakthrough Wilson's Disease Treatment Reverses Brain, Liver, and Kidney Damage in Preclinical Study - Stock Titan
Nuveen Asset Management LLC Purchases New Shares in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome - Reno Gazette Journal
telomir pharmaceuticals reports promising preclinical results for telomir-1 By Investing.com - Investing.com South Africa
EXCLUSIVE: Telomir Pharmaceuticals Lead Drug Shows Promising Signs In Animal Study For Rare Premature Aging Disorder - AOL.com
Telomir Says Lead Candidate Telomir-1 Restored Gene Regulation in Animal Model of Werner Syndrome - MarketScreener
telomir pharmaceuticals reports promising preclinical results for telomir-1 - Investing.com
Telomir Pharmaceuticals-New Data From Preclinical Study Of Its Lead Compound, Telomir-1, In Validated Animal Model Of Werner Syndrome - marketscreener.com
Revolutionary Anti-Aging Drug Resets Biological Clock, Reverses Multiple Aging Markers in Landmark Study - Stock Titan
Telomir Pharmaceuticals Joins BIO Convention for Partnerships - MSN
Telomir announces positive preclinical data for its novel oral AMD therapeutic - Ophthalmology Times
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Increases Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform - Cheboygan Daily Tribune
Telomir Pharmaceuticals To Present At BIO 2025, Eyes IND Filing For Telomir-1 - Nasdaq
Telomir Pharmaceuticals Inc (TELO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):